The German government participates in the financing of the globally active network CARB-X. The program to promote new ideas to tackle the antibiotic resistance crisis will receive €39 million over the next four years. One million euros goes to a German consortium.
The commitment of the Federal Ministry of Research was announced in mid-March at the Novel Antimicrobials and AMR Diagnostics conference in Berlin, and it was decided at the beginning of the month. German and Swiss partners, among others, had already joined the network initiated by British and US institutions at the end of February. So it made sense that Germany should also participate in the financing of CARB-X. The 39 million euros are to benefit the development of antibiotics, vaccines and diagnostics. New approaches and the early phase of product development are in the foreground.
The Federal Ministry of Education and Research (BMBF) is also funding a German consortium with EUR 1 million. The German Center for Infection Research (DZIF) in Braunschweig, the Paul Ehrlich Institute and the Federal Institute for Drugs and Medical Devices (BfArM) are involved. While the DZIF has been part of the CARB-X network since February, the PEI and the BfArM can now also feel part of the global initiative. The entire consortium is considered a member of the network, which now comprises ten partners.
CARB-X stands for Combating Antibiotic Resistant Bacteria Accelerator. Kevin Outterson, head of the accelerator program, expressed his gratitude and honor in Berlin that the Federal Ministry of Research is joining the CARB-X partnership: “We need political and scientific leadership, vision and uninterrupted efforts to win the race with the super germs. ”
In a statement, Federal Research Minister Anja Karliczek pointed out the growing number of pathogens that no longer respond to available therapies. The lives of millions of people around the world are in danger. “Resistant pathogens are spreading worldwide. Combating them therefore requires joint international cooperation measures such as CARB-X. That is why the Federal Ministry of Education and Research supports CARB-X with up to 40 million euros.” Karliczek emphasized that this is just one of the many pieces of the puzzle in the fight against super germs. Overall, Germany has earmarked a budget of 500 million euros, which is to be used to combat antibiotic resistance over the next ten years.
The minister made it clear at the Grand Challenges Annual Meeting in Berlin last fall that Karliczek wants to invest a lot of money in antibiotics research (photo). The BMBF will become a member of the CARB-X Board of Directors, which sets funding strategies and makes investment decisions based on recommendations from the CARB-X Advisory Board. The agreement applies retroactively to January 1, 2019.